Avenzoar Pharmaceuticals, Inc. — Form D
Avenzoar Pharmaceuticals, Inc. of Los Angeles, CA, a company, filed a Form D exempt-offering notice with the SEC on 2019-10-31. The offering totals $918K, of which $525K was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2019-10-31
- Form: D
- Accession: 0001792612-19-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $918K
- Amount sold: $525K
- Remaining: $393K
- Investors: 4
- Date of first sale: 2019-10-17
- Security types: equity, debt
- Revenue range: Decline to Disclose
- SEC file number: 021-352278
Issuer
- Name: Avenzoar Pharmaceuticals, Inc.
- CIK: 0001792612
- Entity type: Corporation
- Jurisdiction: CALIFORNIA
- Incorporated: 2015
- Address: 1819 Outpost Dr., Los Angeles, CA, 90089
- Phone: (310) 502-0770
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Terrance Bruggeman | Director | Encinitas, CA |
| Mouad Edderkaoui | Director | Encinitas, CA |
| Terrance Bruggeman | Executive Officer | Encinitas, CA |
| David Kramer | Executive Officer | Herndon, VA |
| William Reavey | Executive Officer | Encinitas, CA |
| Mark J Chin | Director | Los Angeles, CA |
| Shierley J Widjaja | Director | Los Angeles, CA |
| Stephen J Pandol | Director | Los Angeles, CA |
| Mouad J Edderkaoui | Director | Los Angeles, CA |
| Terrance J Bruggeman | Director | Los Angeles, CA |
| Terrance J Bruggeman | Executive Officer | Los Angeles, CA |
Other filings by this issuer (1)
More